Pharma wants partners not just data suppliers

Share this article:

Form true partnerships with your clients, keep them happy and make your recommendations short and sweet—that's the message from pharma companies to their marketing research suppliers and consultants, according to a new study by marketRx, a Cognizant Company.

Companies felt that the most important attribute they wanted to see in suppliers was their ability to be a partner, rather than simply providing data. Having a positive relationship with them also scored highly, as did suppliers' ability to provide companies with concise summaries of conclusions and recommendations.

However, while most companies generally viewed their experiences with suppliers as positive, they felt that most have considerable room to improve on working with them as partners and on providing concise summaries. Interestingly, companies reported that they were less concerned about their suppliers offering proprietary techniques and providing normative data.

MarketRx presented the results—considered “directional” only—at the Pharmaceutical Marketing Research Group (PMRG) Annual National Conference in Phoenix last month.

The survey also found that the “preferred provider” model is currently dominant (used by 54% of companies) and will be used increasingly in the next five years at the expense of the “no restrictions on suppliers” model.

The “preferred provider” model scored high on “knowledge of therapeutic area” and “cost to the client,” while the “no restrictions” model came out top on “quality.” 
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?